| Bid | 4.8 |
| Market Cap | 132.37M |
| Revenue (ttm) | - |
| Net Income (ttm) | - |
| EPS (ttm) | -2.18 |
| PE Ratio (ttm) | -2.74 |
| Forward PE | n/a |
| Analyst | Buy |
| Ask | 6.16 |
| Volume | 580,409 |
| Avg. Volume (20D) | 254,595 |
| Open | 6.67 |
| Previous Close | 6.54 |
| Day's Range | 5.87 - 6.67 |
| 52-Week Range | 4.32 - 14.74 |
| Beta | undefined |
About INMB
INmune Bio, Inc., a clinical-stage immunotherapy company, focuses on developing drugs to reprogram the patient's innate immune system to treat disease. The company develops and commercializes product candidates to treat hematologic malignancies, solid tumors, and chronic inflammation. Its development programs include INKmune, which focuses on treating women with relapse refractory ovarian carcinoma and patients with high-risk myelodysplastic synd...
Analyst Forecast
According to 2 analyst ratings, the average rating for INMB stock is "Buy." The 12-month stock price forecast is $21, which is an increase of 251.76% from the latest price.
2 weeks ago · seekingalpha.com
INmune Bio: XPro Cognitive Readout In Sight, But Mind The Financial DangersINmune Bio, Inc.'s decline in 2024 is attributed to broader biotech sector issues, lack of significant clinical data, and inherent risks in Alzheimer's research. XPro, INMB's lead candidate, shows pot...
